NCT00503035View on ClinicalTrials.gov

Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 20, 2003

Primary Completion Date

April 2, 2021

Study Completion Date

April 2, 2021

Conditions

Familial Adenomatous Polyposis

Interventions

DRUG

Celecoxib

400 mg by mouth twice daily x 6 months

PROCEDURE

Colonoscopy Biopsy

Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00503035 - Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers | Biotech Hunter | Biotech Hunter